REGN May 2024 905.000 call
| Previous close | 63.88 |
| Open | 74.43 |
| Bid | 72.50 |
| Ask | 82.00 |
| Strike | 905.00 |
| Expiry date | 2024-05-17 |
| Day's range | 74.43 - 74.43 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Simply Wall St.Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 48% Discount?
Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,903 based on 2 Stage Free Cash Flow to Equity...
GlobeNewswireDupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and PARIS, May 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, I
- GlobeNewswire
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition.TARRYTOWN, N.Y. and WASHINGTON, D.C., May 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Innovator Award, named in honor of the pioneer
